BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback